Liverpool HEP Interactions

No Interaction Expected

Sofosbuvir

Diltiazem

Summary:

Coadministration has not been studied. Diltiazem is an inhibitor of P-gp and may increase sofosbuvir concentrations. However, increasing sofosbuvir concentrations has been shown not to increase the predominant metabolite GS-331007, therefore no dose change should be required.

Description:

(See Summary)

No Interaction Expected

Sofosbuvir

Ecstasy (MDMA)

Summary:

Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as ecstasy is metabolised mainly by CYP2D6 which is not affected by sofosbuvir. Sofosbuvir is a prodrug and formation of its active metabolite is unlikely to be affected by comedications.

Description:

(See Summary)

No Interaction Expected

Sofosbuvir

Propafenone

Summary:

Coadministration has not been studied. Propafenone is an inhibitor of P-gp and may increase sofosbuvir concentrations. However, increasing sofosbuvir concentrations has been shown not to increase the predominant metabolite GS-331007, therefore no dose change should be required. Sofosbuvir is a prodrug and formation of its active metabolite is unlikely to be affected by comedications.

Description:

(See Summary)

No Interaction Expected

Sofosbuvir

Medroxyprogesterone (oral)

Summary:

Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Medroxyprogesterone is metabolized by CYP3A4 which is not affected by sofosbuvir. Sofosbuvir is a prodrug and formation of its active metabolite is unlikely to be affected by comedications.

Description:

(See Summary)

No Interaction Expected

Sofosbuvir

Molly (Ecstasy, MDMA)

Summary:

Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as ecstasy is metabolised mainly by CYP2D6 which is not affected by sofosbuvir. Sofosbuvir is a prodrug and formation of its active metabolite is unlikely to be affected by comedications.

Description:

(See Summary)

No Interaction Expected

Sofosbuvir

E (Ecstasy, MDMA)

Summary:

Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as ecstasy is metabolised mainly by CYP2D6 which is not affected by sofosbuvir. Sofosbuvir is a prodrug and formation of its active metabolite is unlikely to be affected by comedications.

Description:

(See Summary)

Generate a personalised report in PDF format